Feasibility of FLAG-IDA regimen in cases with relapsed/refractory acute leukemia cases

WOS: 000233486000012PubMed ID: 16252088

Feasibility of FLAG-IDA regimen in cases with relapsed/refractory acute leukemia cases [3]

PubMedID: 16252088[No abstract available

Granulomatous orchitis mimicking Hodgkin's lymphoma relapse

PubMedID: 14502265[No abstract available

Hepatitis B virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma

PubMedID: 12916882[No abstract available

Ovarian granulocytic sarcoma

PubMedID: 15061218Granulocytic sarcoma (GS) or chloroma is a neoplasia of immature myeloid cells. Bones, skins, soft tissues and lymph nodes are the most frequently involved organs with this entity and not infrequently it is diagnosed histopathologically as non-Hodgkin's lymphoma (NHL). Ovarian granulocytic sarcoma is a rare entity in daily practice. Here we report an ovarian granulocytic sarcoma, initially diagnosed as NHL, and review the literature

IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: A single-center experience

PubMedID: 16988532We evaluated efficacy and toxicity profiles of fludarabine, Ara-C, idarubicin, and G-CSF (Ida-FLAG) combination chemotherapy in 56 refractory and/or relapsed acute leukemia patients. Patients were treated with fludarabine phosphate 25 mg/m/d (d1-5), Ara-C 2 g/m/d (d1-5), idarubicin 12 mg/m/d (d1-3), G-CSF was given subcutaneously from sixth day until absolute neutrophil count (ANC) >500/µL. One third of the acute myeloblastic leukemia (AML) and 45% of acute lymphoblastic leukemia (ALL) cases were primary refractory disease. In AML patients, complete remission (CR) was achieved in 15 cases (53.6%). One case showed partial remission (PR) (3.6%) and 12 cases (42.8%) had resistant to this regimen (RD). Grade IV hematologic toxicity occurred in all AML cases. Leukocyte recovery time was 16 days. Nonhematologic complications were mild to moderate nausea, vomiting, and mucositis and could be controlled by routine measures. Stem cell transplantation was performed in 5 patients and all achieved CR, 2 autologous and 3 allogeneic. In ALL patients, CR and PR were obtained in 8 (42.2%) and 2 (10.5%) of 22 cases; disease was resistant to Ida-FLAG in 9 (47.3%) cases. Grade IV hematologic toxicity occurred in all ALL cases. Leukocyte recovery time was 17 days. Nonhematologic toxicity consisted of nausea, vomiting, and mucositis and could be controlled by supportive therapy. Autologous transplantation was performed in 1 patient, but relapse disease occurred after 5 weeks. There was no correlation between response rate and leukemia subtype (AML versus ALL), leukocyte count, age, sex, disease status (de novo versus secondary), and RFS (early versus late relapse) (P > 0.05). Median survival was 16 weeks in all cases (22 weeks in AML versus 13 weeks). At present, only 3 patients are alive and 2 of these are in continuous remission. The rest of the patients died. In conclusion, Ida-FLAG is a good choice in cases with refractory/relapsing acute leukemia for salvage chemotherapy. High efficacy and a low-toxicity profile are preferable properties of this regimen, and this regimen has been found to be useful for cytoreduction, especially in candidates for allo-SCT. © 2006 Lippincott Williams & Wilkins

Fludarabine as the possible cause of acute myelofibrosis [3]

PubMedID: 15167919[No abstract available

Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab

PubMedID: 20357439Fludarabine is a nucleoside analogue used in the treatment of low-grade lymphoproliferative disorders and in conditioning regimens of non-myeloablative allogeneic stem cell transplantation. This is a relatively safe drug for clinical use but may cause side effects, some of which may be life-threatening. Here a case of severe pulmonary toxicity associated with fludarabine and a possible contribution of rituximab is presented and the literature reviewed. Copyright © 2010 S. Karger AG, Basel

Fludarabine as the possible cause of acute myelofibrosis

WOS: 000227379000016PubMed ID: 15167919

Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase [3]

PubMedID: 14959867[No abstract available